Registration - In-house Corporation

Pharmascience Inc. / David Goodman, Chief Executive Officer

Registration Information

In-house Corporation name: Pharmascience Inc.
Responsible Officer Name: David Goodman, Chief Executive Officer
Responsible Officer Change History
Initial registration start date: 2009-02-02
Registration status: Active
Registration Number: 725814-234102

Associated Communications

Total Number of Communication Reports: 56

Monthly communication reports in the last 6 months: 1

Version 22 of 29 (2023-06-19 to 2024-05-14)

Registration versions:

Version 22 of 29 (2023-06-19 to 2024-05-14)

Lobbying Information

Subject Matters

Economic Development
Government Procurement
Health
Industry
Intellectual Property
International Trade
Municipalities
Regional Development
Research and Development
Science and Technology
Taxation and Finance

Subject Matter Details

Grant, Contribution or Other Financial Benefit

Seeking support from the Strategic Innovation Fund Program for support of biomanufacturing expansion project.

Policies or Program

Discussion of a possible Therapeutics Products Directorate ("TPD") workstream on complex generics regulatory pathways.
Discussion of regulatory impediments to the launch of pediatric formulations of branded and generic products.
Discussion on the opioids crisis and the Health minister's expectations from pharmaceutical manufacturers
Policies aimed at facilitating generic drugs repurposing.
Policies aimed at reinforcing pharmaceutical supply chain.

Communication Techniques

Written communication
Oral communication
Grass-roots communication

Government Institutions

Finance Canada (FIN)
Global Affairs Canada (GAC)
Health Canada (HC)
House of Commons
Innovation, Science and Economic Development Canada (ISED)
Prime Minister's Office (PMO)
Transport Canada (TC)

In-house Corporation Details

Description of activities

Pharmascience Inc. is a Canadian-owned pharmaceutical company specializing in the manufacturing and distribution of generic, innovative, and consumer brand pharmaceutical products in Canada

Responsible officer name and position during the period of this registration

Martin Arès, Chief Executive Officer

Government funding

End date of the last completed financial year: 2023-05-31

List of Government Funding
Government Institution	Funding Received in Last Financial Year	Funding Expected in Current Financial Year
Innovation, Science and Economic Development Canada (ISED)	$0.00	Yes
Investissement Québec	$94,719.38	Yes

In-house Corporation Contact Information

Address:
6111 Royalmount avenue, suite 100
Montreal, QC H4P 2T4
Canada

Telephone number: 514-340-9800

Parent Company Information

Finchley Pharmaceuticals Inc. / Finchley pharmaceutiques inc.
- 6111 Royalmount Avenue, suite 150
  Montreal, QC H4P 2T4
  Canada

Subsidiary Beneficiary Information

Pharmascience Inc. does not have any subsidiaries that could have a direct interest in the outcome of the undertaking

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Martin Arès, Chief Executive Officer | No public offices held
David Goodman, Executive Chairman | No public offices held
Morris Goodman, Co-Founder | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Sarah E Douglas, Head, Government & Public Affairs | Public offices held
Ken Gagnon, Senior Manager, Government Affairs | No public offices held

Pharmascience Inc.

The following names have been used on or after July 2, 2008

Name	From	To
Pharmascience Inc.	2009-02-02	current

Pharmascience Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
David Goodman	2025-02-17	Current
Martin Arès	2023-01-03	2025-02-17
David Goodman	2009-02-02	2023-01-03

List of Public Offices Held
Position	Period Held	Last Date Designated Public Office Held
Press Secretary (Ontario) House of Commons, Office of the Leader of t he Official Opposition	January 2013 to September 2013	Not a designated office
Press Secretary (Ontario) - Acting House of Commons, Office of the Leader of the Official Opposition	October 2012 to December 2012	Not a designated office
Communications Officer - Writer House of Commons, Office of the Leader of t he Official Opposition	February 2012 to September 2012	Not a designated office
Parliamentary Assistant House of Commons, Office of Jamie Nicholls, MP	July 2011 to February 2012	Not a designated office
Member's Assistant House of Commons, Office of Judy Wasylycia-Leis, MP	March 2010 to March 2010	Not a designated office
Research Assistant House of Commons, Office of John Rafferty, MP	September 2008 to March 2011	Not a designated office

Date Modified:: 2025-04-30

Search and menus

Language selection

Registration - In-house Corporation

Pharmascience Inc. / David Goodman, Chief Executive Officer

Registration Information

Associated Communications

Version 22 of 29 (2023-06-19 to 2024-05-14)

Version 22 of 29 (2023-06-19 to 2024-05-14)

Subject Matters

Subject Matter Details

Grant, Contribution or Other Financial Benefit

Policies or Program

Communication Techniques

Government Institutions

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties